CytomX/$CTMX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CytomX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Ticker
$CTMX
Sector
Primary listing
Employees
120
Headquarters
Website
CytomX Metrics
BasicAdvanced
$338M
4.19
$0.49
2.13
-
Price and volume
Market cap
$338M
Beta
2.13
52-week high
$3.10
52-week low
$0.40
Average daily volume
3.1M
Financial strength
Current ratio
4.197
Quick ratio
4.078
Long term debt to equity
1.203
Total debt to equity
5.742
Profitability
EBITDA (TTM)
44.7
Gross margin (TTM)
100.00%
Net profit margin (TTM)
34.01%
Operating margin (TTM)
30.56%
Effective tax rate (TTM)
0.52%
Revenue per employee (TTM)
$1,180,000
Management effectiveness
Return on assets (TTM)
16.13%
Return on equity (TTM)
108.21%
Valuation
Price to earnings (TTM)
4.192
Price to revenue (TTM)
1.407
Price to book
2.82
Price to tangible book (TTM)
2.85
Price to free cash flow (TTM)
-2.555
Free cash flow yield (TTM)
-39.14%
Free cash flow per share (TTM)
-0.802
Growth
Revenue change (TTM)
18.01%
Earnings per share change (TTM)
265.60%
3-year revenue growth (CAGR)
73.65%
10-year revenue growth (CAGR)
34.00%
3-year earnings per share growth (CAGR)
-39.11%
10-year earnings per share growth (CAGR)
-32.65%
What the Analysts think about CytomX
Analyst ratings (Buy, Hold, Sell) for CytomX stock.
CytomX Financial Performance
Revenues and expenses
CytomX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CytomX stock?
CytomX (CTMX) has a market cap of $338M as of August 29, 2025.
What is the P/E ratio for CytomX stock?
The price to earnings (P/E) ratio for CytomX (CTMX) stock is 4.19 as of August 29, 2025.
Does CytomX stock pay dividends?
No, CytomX (CTMX) stock does not pay dividends to its shareholders as of August 29, 2025.
When is the next CytomX dividend payment date?
CytomX (CTMX) stock does not pay dividends to its shareholders.
What is the beta indicator for CytomX?
CytomX (CTMX) has a beta rating of 2.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.